Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics (NASDAQ:AKBA) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.

Do analysts prefer AKBA or SDGR?

Akebia Therapeutics currently has a consensus target price of $6.63, suggesting a potential upside of 176.62%. Schrödinger has a consensus target price of $33.00, suggesting a potential upside of 30.93%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akebia Therapeutics is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Schrödinger	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in AKBA or SDGR?

Akebia Therapeutics received 366 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 63.17% of users gave Akebia Therapeutics an outperform vote while only 58.33% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Akebia Therapeutics	Outperform Votes 422 63.17%	Underperform Votes 246 36.83%
Schrödinger	Outperform Votes 56 58.33%	Underperform Votes 40 41.67%

Which has more risk and volatility, AKBA or SDGR?

Akebia Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Does the media prefer AKBA or SDGR?

In the previous week, Akebia Therapeutics had 5 more articles in the media than Schrödinger. MarketBeat recorded 12 mentions for Akebia Therapeutics and 7 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.91 beat Akebia Therapeutics' score of 0.87 indicating that Schrödinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrödinger	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AKBA or SDGR more profitable?

Akebia Therapeutics has a net margin of -27.07% compared to Schrödinger's net margin of -91.84%. Akebia Therapeutics' return on equity of 0.00% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-27.07%	N/A	-20.57%
Schrödinger	-91.84%	-35.77%	-24.51%

Do institutionals & insiders hold more shares of AKBA or SDGR?

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 4.1% of Akebia Therapeutics shares are owned by insiders. Comparatively, 8.6% of Schrödinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has stronger valuation and earnings, AKBA or SDGR?

Schrödinger has higher revenue and earnings than Akebia Therapeutics. Schrödinger is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$160.18M	3.53	-$51.92M	-$0.33	-7.26
Schrödinger	$207.54M	8.87	$40.72M	-$2.57	-9.81

Summary

Akebia Therapeutics beats Schrödinger on 10 of the 18 factors compared between the two stocks.